A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness Study (NORD-FACE)

First published 23/06/2021

Last updated 12/03/2025

EU PAS number:

EUPAS41175

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

Protocol-Merck_NORD-FACE_Study_v1.0_27May2021

English (6.22 MB - PDF)View document

Study results

Study report

EUPAS_EUPAS41175_NORDFACE Study_Abbreviated Study Report_Redacted For Publication.pdf

English (215.29 KB - PDF)View document

Other information

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

DoIForm_v1.6_Investigators

English (3.28 MB - PDF)View document

Composition of steering group and observers

NORD-FACE EU PAS 41175_No Steering Group and Observers

English (59.93 KB - PDF)View document

Signed code of conduct

empty_file.pdf

English (11.35 KB - PDF)View document

Signed code of conduct checklist

empty_file.pdf

English (11.35 KB - PDF)View document

Signed checklist for study protocols

empty_file.pdf

English (11.35 KB - PDF)View document

Secondary tabs

Share this page